Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor

• US 20170266270A1
• Filed: 05/08/2015
• Published: 09/21/2017
• Est. Priority Date: 05/13/2014
• Status: Abandoned Application

• Current Assignee: Bavarian Nordic A/S
• Original Assignee: Bavarian Nordic A/S
• Inventors: FOY, SUSAN, MANDL, STEFANIE, ROUNTREE, RYAN, FRANZUSOFF, ALEX
• Application Number:
  US15/310,405
• Publication Number:
  US 20170266270A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 35/76 Viruses; Subviral particles; Bacteriophages
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001106 Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
• CPC Class Codes: A61K 39/00115 Apoptosis related proteins, e.g. survivin or livin
• CPC Class Codes: A61K 39/00117 Mucins, e.g. MUC-1
• CPC Class Codes: A61K 39/001182 Carcinoembryonic antigen [CEA]
• CPC Class Codes: A61K 39/001193 Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
• CPC Class Codes: A61K 39/001194 Prostate specific antigen [PSA]
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/464406 Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 2710/24041 Use of virus, viral particle or viral elements as a vector
• CPC Class Codes: C12N 2710/24141 : Use of virus, viral particle or viral elements as a vector
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with antagonists or agonists of immune checkpoint inhibitors.

Claims

1-132. -132. (canceled)

133. A method for treating a human cancer patient comprising:

(a) administering to the patient a recombinant poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA); and

(b) administering to the patient a PD-1 antagonist and a CTLA-4 antagonist.

134. The method of claim 133, wherein the PD-1 antagonist and the CTLA-4 antagonist comprise an anti-PD-1 antagonist antibody and an anti-CTLA-4 antibody, respectively.

135. The method of claim 134, wherein the poxvirus is selected from an orthopoxvirus and an avipoxvirus.

136. The method of claim 135, wherein the orthopoxvirus is a vaccinia virus.

137. The method of claim 136, wherein the vaccinia virus is a modified vaccinia Ankara (MVA) virus.

138. The method of claim 137, wherein the MVA is MVA-BN.

139. The method of claim 135, wherein the avipox virus is a fowlpox virus.

140. The method of claim 133, wherein the at least one TAA is selected from the group consisting of:

carcinoembryonic antigen (CEA), mucin 1 cell surface associated (MUC-1), prostatic acid phosphatase (PAP), prostate specific antigen (PSA), human epidermal growth factor receptor 2 (HER-2), survivin, tyrosine related protein 1 (tyrp1), tyrosine related protein 1 (tyrp2), Brachyury, and combinations thereof.

141. The method of claim 140, wherein the at least one TAA is CEA and MUC-1.

142. The method of claim 140, wherein the at least one TAA is PSA.

143. The method of claim 142, wherein the at least one TAA is PAP.

144. The method of claim 140, wherein the at least one TAA is HER-2.

145. The method of claim 140, wherein the cancer treatment is directed against breast cancer, lung cancer, head and neck cancer, thyroid, melanoma, gastric cancer, bladder cancer, kidney cancer, liver cancer, melanoma, pancreatic cancer, prostate cancer, ovarian cancer, or colorectal cancer.

146. The method of claim 142, wherein the cancer treatment is directed against prostate cancer.

147. The method of claim 144, wherein the cancer treatment is directed against a cancer selected from breast cancer, colorectal cancer, and lung cancer

148. A method for treating cancer in a human cancer patient, the method comprising administering to the patient a combination of:

(a) a therapeutically effective amount of a recombinant poxvirus, the poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA); and

(b) a therapeutically effective amount of at least one immune checkpoint antagonist or agonist, wherein the therapeutically effective amount of the at least one immune checkpoint antagonist or agonist is such that the therapeutic effect of the combination is increased as compared to an administration of either (1) the poxvirus vector encoding a polypeptide comprising at least one TAA alone or (2) the at least one immune checkpoint antagonist or agonist alone or in combination with other immune checkpoint antagonists or agonists.

149. The method of claim 148, wherein the immune checkpoint antagonist or agonist comprises a PD-1 antagonist.

150. The method of claim 148, wherein the immune checkpoint antagonist or agonist comprises a CTLA-4 antagonist.

151. The method of claim 148, wherein the immune checkpoint antagonist or agonist comprises a PD-1 antagonist and a CTLA-4 antagonist.

152. The method of claim 151, wherein the PD-1 antagonist and the CTLA-4 antagonist is an anti-PD-1 antibody and an anti-CTLA-4 antibody, respectively.

153. The method of claim 148, wherein the immune checkpoint antagonist or agonist is administered at an amount of about 1 mg/kg to about 3 mg/kg of the patient'"'"'s body weight.

154. The method of claim 153, wherein the immune checkpoint antagonist or agonist is administered at an amount of about 1 mg/kg of the patient'"'"'s body weight.

155. The method of claim 148, wherein the therapeutically effective amount of a recombinant poxvirus in combination with the therapeutically effective amount of an immune checkpoint antagonist or agonist is administered as part of a homologous or a heterologous prime-boost regimen;

wherein the homologous prime-boost regimen comprises a first prime dose of the recombinant poxvirus in combination with the immune checkpoint antagonist or agonist and one or more subsequent boost doses of a same recombinant poxvirus in combination with the immune checkpoint antagonist or agonist; and

wherein the heterologous prime-boost regimen comprises a first prime dose of the recombinant poxvirus in combination with the immune checkpoint antagonist or agonist and one or more subsequent boost doses of a different recombinant poxvirus in combination with the immune checkpoint antagonist or agonist.

156. The method of claim 155, wherein the recombinant poxvirus in combination with the immune checkpoint antagonist or agonist is administered as part of a heterologous prime-boost regimen, wherein the recombinant poxvirus of the first prime dose comprises an orthopoxvirus and the recombinant poxvirus of one or more the boosting doses comprises an avipoxvirus.

157. The method of claim 156, wherein the orthopoxvirus is selected from vaccinia virus, MVA, or MVA-BN.

158. The method of claim 148, wherein the at least one TAA is selected from the group consisting of:

HER2, MUC-1, CEA, PSA, PAP, and combinations thereof.

159. A pharmaceutical combination for treating cancer in a human patient, the combination comprising:

(a) a recombinant poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA);

(b) a PD-1 antagonist; and

(c) a CTLA-4 antagonist.

160. The pharmaceutical combination of claim 159, wherein the PD-1 antagonist and the CTLA-4 antagonist comprises an anti-PD-1 antagonist antibody and an anti-CTLA-4 antibody, respectively.

161. The pharmaceutical combination of claim 160, wherein the at least one TAA is selected from the group consisting of:

CEA, MUC-1, PAP, PSA, HER-2, survivin, tyrosine related protein 1 (tyrp1), tyrosine related protein 2 (tyrp2), Brachyury antigen, and combinations thereof.

162. The pharmaceutical combination of claim 161, wherein the at least one TAA is PSA.

163. The pharmaceutical combination of claim 162, wherein the at least one TAA is MUC-1 and CEA.

164. The pharmaceutical combination of claim 160, wherein the poxvirus is an orthopoxvirus or an avipox virus.

165. The pharmaceutical combination of claim 164, wherein the orthopoxvirus is selected from vaccinia, MVA, or MVA-BN

166. The pharmaceutical combination of claim 164, wherein the avipoxvirus is fowlpox virus.

167. A pharmaceutical combination for treating cancer in a human patient, comprising:

(a) a therapeutically effective amount of a recombinant poxvirus, the poxvirus encoding a polypeptide comprising at least one tumor associated antigen (TAA); and

(b) a therapeutically effective amount of at least one immune checkpoint antagonist or agonist, wherein the therapeutically effective amount of the at least one immune checkpoint antagonist or agonist is such that the therapeutic effect of the combination is increased as compared to an administration of either (1) the poxvirus vector encoding a polypeptide comprising at least one TAA alone or (2) the at least one immune checkpoint antagonist or agonist alone or in combination with other immune checkpoint antagonists or agonists.

168. The pharmaceutical combination of claim 167, wherein the at least one immune checkpoint antagonist or agonist is selected from group consisting of:

a PD-1 antagonist, a CTLA-4 antagonist, a TIM-3 antagonist, a LAG-3 antagonist, an ICOS agonist, and combinations thereof.

169. The pharmaceutical combination of claim 168, wherein the at least one TAA is selected from the group consisting of:

carcinoembryonic antigen (CEA), mucin 1 cell surface associated (MUC-1), prostatic acid phosphatase (PAP), prostate specific antigen (PSA), human epidermal growth factor receptor 2 (HER-2), survivin, tyrosine related protein 1 (tyrp1), tyrosine related protein 1 (tyrp2), Brachyury, and combinations thereof.